Imaging for Metastasis in Prostate Cancer: A Review of the Literature

Frontiers in Oncology

David Pasquier²  Philippe Puech⁴  Jonathan Olivier⁵  Arnauld Villers⁵  Edwina Girard⁶  Nicolas Penel⁶  Clio Baillet⁷  Anthony Turpin⁸ 

[1] Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France;CRISTAL UMR CNRS 9189, Lille University, Villeneuve-d'Ascq, France;Department of Medical Oncology, CHU Lille, Lille, France;Department of Radiology, CHU Lille, Lille, France;Department of Urology, CHU Lille, Lille, France;Medical Oncology Department, Centre Oscar Lambret, Lille, France;Nuclear Medicine Department, CHU Lille, Lille, France;Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 – UMR-S 1277 – Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France;

关键词: prostate cancer;    choline-PET;    fluciclovine-PET;    PSMA-PET;    bone scan;    MRI;   

DOI  :  10.3389/fonc.2020.00055

来源: DOAJ

【 摘 要 】

Background: Initial staging and assessment of treatment activity in metastatic prostate cancer (PCa) patients is controversial. Indications for the various available imaging modalities are not well-established due to rapid advancements in imaging and treatment.Methods: We conducted a critical literature review of the main imaging abnormalities that suggest a diagnosis of metastasis in localized and locally advanced PCa or in cases of biological relapse. We also assessed the role of the various imaging modalities available in routine clinical practice for the detection of metastases and response to treatment in metastatic PCa patients.Results: In published clinical trials, the most commonly used imaging modalities for the detection and evaluation of therapeutic response are bone scan, abdominopelvic computed tomography (CT), and pelvic and bone magnetic resonance imaging (MRI). For the detection and follow-up of metastases during treatment, modern imaging techniques i.e., choline-positron emission tomography (PET), fluciclovine-PET, or Prostate-specific membrane antigen (PSMA)-PET provide better sensitivity and specificity. This is particularly the case of fluciclovine-PET and PSMA-PET in cases of biochemical recurrence with low values of prostate specific antigen.Conclusions: In routine clinical practice, conventional imaging still have a role, and communication between imagers and clinicians should be encouraged. Present and future clinical trials should use modern imaging methods to clarify their usage.

【 授权许可】

Unknown